We continue to monitor the COVID-19 situation closely and engage with manufacturers, industry partners and government agencies to anticipate shortages and respond to demand for certain medications and therapies. We know the potential for drug shortages or supply disruption is an area of great concern to our customers.

As potential shortages or disruptions of products are identified, we’re acting to address supply continuity. Here are just a few steps we’ve taken to help mitigate possible COVID-19 pharmaceutical supply disruptions.

We have:

  • Secured additional product when available
  • Sourced back-up products when needed
  • Followed allocation procedures to triage the distribution of medicine
  • Initiated business continuity action planning to maintain and protect operations across all locations and facilities

Additional products

We are dedicated to our customers and the patients they serve. So, we have put forth the full weight of our company and leveraged every resource to help keep the supply chain moving.

Steps we’ve taken:

  • Assembled a Critical Care Drug Task Force (CCDTF) made up of our procurement specialists and clinical health systems pharmacists to review guidelines and protocols as they are released to forecast changing pharmaceutical demand
  • Channeled critical product inventory to geographic areas and sites of care with greatest need
  • Set up 24/7 emergency triage response service, as well as a responsive process to evaluate and increase allocations

Sourcing

We work with pharmaceutical manufacturers through several channels, including our ClarusONE and Global sourcing teams in London. Our leaders are actively engaged in addressing potential shortages. We have also engaged with industry partners and government agencies to gain visibility into true supply and demand. In addition, we’re tracking manufacturers’ steps to scale up production or create new capacity, and allocation methodologies to make sure we get medications to the right place.

Allocations

The situation remains fluid and we are taking a proactive approach to protect inventory during this crisis and make sure our provider partners have needed supplies and medications to treat those that are ill and to help stop the spread of the disease.

While we are working to make product available to all our customers, we have a special focus on acute and long-term-care pharmacies that face significant challenges during this crisis. We will continue to closely and frequently monitor the product needs of these customer classes to identify increased demand and try to prevent future product supply issues.

Business continuity

As a leading distributor of medications and other healthcare-related products, we have a robust Business Continuity and Disaster Recovery Program (BCRP).

Our priorities are to:

  • Protect the supply chain to minimize disruption in healthcare
  • Promote the safety of our employees
  • Maintain workplaces that are safe and secure
  • Continue critical business processes following natural disasters, human caused threats, and other incidents

We will continue to enact our BCRP in response to the pandemic, if needed. In the event of workforce impact, we have several options that will be considered and utilized as appropriate:

  • Network resilience and redundancy
  • Alternate source and back-up product from hub locations through our delivery partners
  • Workforce continuity plans:
    • We have established relationships with temp agencies to secure labor
    • In response to extreme impact, we may limit or match demand with capacity to make sure all customers are serviced. This could include limiting deliveries, limiting lines, prioritizing medications and/or longer lead times to service from other areas
     

top